PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine.
According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days.
Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from February 27, 2025 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn your rights, CLICK HERE.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
